Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed patients who received a sibling tandem auto-allo (HSCT) with an

leukemia
graft versus host disease
lenalidomide
plasma cell leukemia
measurable disease
  • 65 views
  • 15 Mar, 2022
  • 1 location
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted …

monoclonal protein
leukemia
inotuzumab
kinase inhibitor
tyrosine
  • 15 views
  • 21 Mar, 2022
  • 1 location
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement (relapsed) or has not responded to treatment (refractory). Immunotherapy with …

  • 43 views
  • 19 Sep, 2022
  • 3 locations
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. (TETRAVI)

allogeneic hematopoietic stem cell transplant (HSCT). These cells may also have value in CAR-T recipients who have received a product that depletes virus specific T cells. The patient must have had a

methylprednisolone
cmv infection
  • 1 views
  • 25 Mar, 2022
  • 2 locations
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

myelodysplastic syndrome (MDS) which has come back, or may come back, or has not gone away after standard treatment, including an allogeneic hematopoietic stem cell transplant (HSCT). The investigators

leukemia
chromosome abnormality
bone marrow procedure
myeloid leukemia
white blood cell count
  • 54 views
  • 15 Jun, 2022
  • 2 locations
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Background Sickle cell disease (SCD) is an inherited blood disorder. It results from a single genetic change (mutation) in red blood cells (RBCs). RBCs are the cells that carry oxygen to the body. In people with SCD, some RBCs are abnormal and die early. This leaves a shortage of healthy …

bone marrow transplant
hemoglobin s
Accepts healthy volunteers
blood disorder
anemia
  • 7 views
  • 22 Jul, 2022
  • 1 location
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell transplants. The researchers will compare two different drug combinations used to reduce the risk of a …

hla class i antigen
cyclophosphamide
prolymphocytic leukemia
transplant conditioning
blood stem cell transplant
  • 64 views
  • 05 Jun, 2022
  • 1 location
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

This phase Ib/2 trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant. Drugs used in the chemotherapy, such as fludarabine phosphate and melphalan hydrochloride, work in different ways …

leukemia
radiation oncology
cyclophosphamide
transplant conditioning
cancer
  • 45 views
  • 12 May, 2022
  • 1 location
Positive Psychology Intervention In HSCT (PATH-3)

The main purpose of this research study is to determine if a positive psychology-based program in people who have received a stem cell transplant for blood cancer treatment is feasible and acceptable, and can help improve positive feelings, mood, quality of life, overall wellbeing and health. The Positive psychology for …

cancer
  • 0 views
  • 23 Mar, 2022
  • 1 location
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have returned after a period of improvement (relapsed) undergoing a second donor stem …

leukemia
hematologic malignancy
fludarabine
cell transplantation
myeloid leukemia
  • 13 views
  • 25 Mar, 2022
  • 1 location